RxDoctor Payments Data

Alison Vukich, MD

Family Medicine · Jacksonville, FLNPI 1245282482

Payments from drug & device makers

$8,026in general payments, 2019–2025

Across 454 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$697
  • AbbVie$602
  • Lilly USA, LLC$598
  • Pfizer$596
  • Boehringer Ingelheim$462
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$8,020100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,026 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$82,234
Medicare patients
166
Services billed
1,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$121,219
JardianceEmpagliflozin50$54,600
TrulicityDulaglutide45$49,413
MounjaroTirzepatide38$45,258
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$38,490
EliquisApixaban43$37,585
Repatha SureclickEvolocumab25$25,071
FarxigaDapagliflozin Propanediol21$24,598
JanuviaSitagliptin Phosphate21$19,780
Rosuvastatin Calcium287$3,356
Montelukast Sodium212$2,937
Nebivolol Hcl45$2,647
Levothyroxine Sodium238$2,254
Pregabalin73$2,095
Amlodipine Besylate280$1,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,024$121,21988 claims
Lilly USA, LLCTrulicity, Mounjaro$598$94,67183 claims
Boehringer IngelheimJardiance$462$54,60050 claims
GSKTrelegy Ellipta$448$38,49054 claims
PfizerEliquis$596$37,58543 claims
AstraZenecaFarxiga$697$24,59821 claims
MerckJanuvia$301$19,78021 claims
AbbVieSynthroid$602$1,76038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →